多柔比星(DOXO)是一种抗肿瘤药物,广泛用于治疗多种癌症。然而,DOXO引起的心脏毒性是其广泛使用的限制因素,并极大地影响患者的生活质量。法尼醇(FSN)是一种具有抗氧化剂的倍半萜,抗炎,和抗肿瘤特性。因此,本研究探讨了FSN对DOXO诱导的心脏毒性的心脏保护作用。在这项研究中,雄性Wistar大鼠随机分为5组(n=7),治疗14天。I组(对照):生理盐水,每日口服,持续14天;第二组(毒性):DOXO2.4mg/kg,i.p,每周三次,共14天;第三组:FSN100mg/kg,每日口服,持续14天+DOXO,类似于第二组;第四组:FSN200mg/kg,每日口服,持续14天+类似于第二组的DOXO;第五组(标准):硝苯地平10mg/kg,每天p.o.14天+DOXO类似于第II组。在研究结束时,动物称重,采集血液,测量心脏重量。心脏组织用于评估生化标志物和组织病理学研究。观察结果表明,FSN治疗组大鼠的心脏重量和心脏重量/体重比降低,逆转了氧化应激,心脏特异性损伤标志物,促炎和促凋亡标志物和组织病理学对正常,并显示出心脏保护。总之,FSN通过其抗氧化剂减少由DOXO引起的心脏损伤,抗炎,和抗凋亡潜能。然而,需要更详细的基于机制的研究才能将该药物用于临床.
Doxorubicin (DOXO) is an antineoplastic drug that is used extensively in managing multiple cancer types. However, DOXO-induced cardiotoxicity is a limiting factor for its widespread use and considerably affects patients\' quality of life. Farnesol (FSN) is a sesquiterpene with antioxidant, anti-inflammatory, and anti-tumor properties. Thus, the current
study explored the cardioprotective effect of FSN against DOXO-induced cardiotoxicity. In this
study, male Wistar rats were randomly divided into five groups (n = 7) and treated for 14 days. Group I (Control): normal saline, p.o. daily for 14 days; Group II (TOXIC): DOXO 2.4 mg/kg, i.p, thrice weekly for 14 days; Group III: FSN 100 mg/kg, p.o. daily for 14 days + DOXO similar to Group II; Group IV: FSN 200 mg/kg, p.o. daily for 14 days + DOXO similar to Group II; Group V (Standard): nifedipine 10 mg/kg, p.o. daily for 14 days + DOXO similar to Group II. At the end of the
study, animals were weighed, blood was collected, and heart-weight was measured. The cardiac tissue was used to estimate biochemical markers and for histopathological studies. The observed results revealed that the FSN-treated group rats showed decrease in heart weight and heart weight/body weight ratio, reversed the oxidative stress, cardiac-specific injury markers, proinflammatory and proapoptotic markers and histopathological aberrations towards normal, and showed cardioprotection. In summary, the FSN reduces cardiac injuries caused by DOXO via its antioxidant, anti-inflammatory, and anti-apoptotic potential. However, more detailed mechanism-based studies are needed to bring this drug into clinical use.